This site is intended for health professionals only

Drug may improve Herceptin effects

teaser

Roche’s multibillion-dollar breast-cancer treatment Herceptin may be boosted by the addition of an experimental drug, according to its partner ImmunoGen, which develops targeted cancer therapeutics.

T-DM1 is a second-generation treatment, which combines Herceptin (trastuzumab) with an ImmunoGen-developed tumour-killing chemotherapy payload.

The Genentech unit at Roche is to start a study of T-DM1, which has not yet been approved for use, in May 2010. An adjuvant trial is also in the planning stages.

Article continues below this sponsored advert
Advertisement

The goal of the trials to see is T-DM1 can one day replace Herceptin as the leading treatment for women with certain breast cancers.

Herceptin global sales totalled $3.8 billion (£2.3 billion) in the first nine months of 2009 and $4.7 billion in sales in 2008.

Copyright Press Association 2009






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x